Cristin-prosjekt-ID: 2537845
Registrert av: REK Sist endret: 14. april 2022, 09:09 Sist endret av: REK

Cristin-prosjekt-ID: 2537845
Registrert av: REK Sist endret: 14. april 2022, 09:09 Sist endret av: REK
Prosjekt

4- dagers behandling av oppkast-fobi: Tilpassing og klinisk effektivitet

prosjektleder

Gerd Kvale
ved Helse Bergen HF - Haukeland universitetssykehus

prosjekteier / koordinerende forskningsansvarlig enhet

  • Helse Bergen HF - Haukeland universitetssykehus

Godkjenninger

  • Regionale komitéer for medisinsk og helsefaglig forskningsetikk (REK) - 417836

Kategorier

Helseprosjekttype

Annet klinisk behandlingsstudium

Tidsramme

Aktivt
Start: 15. februar 2022 Slutt: 15. februar 2028

Beskrivelse Beskrivelse

Tittel

4- dagers behandling av oppkast-fobi: Tilpassing og klinisk effektivitet

Populærvitenskapelig sammendrag

The Bergen 4-day treatment (B4DT) is a highly concentrated format of exposure and response prevention developed for obsessive compulsive disorder (OCD). It has proven to be effective for OCD with little and no dropout and the results are maintained for at least four years (Hansen, Kvale, Hagen and Öst, 2018). In a recent randomized controlled trial, B4DT yielded better results than self-help and waiting list (Launes et al., 2919). This treatment format has successfully been adapted to panic disorder in Norway (Hansen et al., 2018) and implemented for OCD at the Icelandic Anxiety Clinic (Kvíðameðferðarstöðin, KMS) with equally good results (Davidsdottir et al., 2019). Emetophobia, or specific phobia of vomiting, is a debilitating and scaresly studied disorder that shares features with OCD, panic disorder and health anxiety. It is treated individually at KMS and generally considered more complex and challenging to treat than other types of specific phobia. According to the few studies conducted on emetophobia´s treatment, at most 60% of patients receiving CBT for emetophobia obtain clinically significant change and there is some dropout from treatment (Ahlen, Edberg, Di Schiena and Bergström, 2014, Keyes, Deale, Foster and Veale, 2018, Riddle-Walker et al., 2016). Intensive CBT seems to be the most promising treatment format, although not optimally effective, and some researchers have concluded that patients may need more therapy assisted exposure similar to stepped care in OCD (Veale, Naismith, Miles and Childs, 2016). The B4DT may be a particularly suitable treatment format for emetophobia, as OCD and emetophobia have overlapping features, and intensive CBT is already proven to be at least moderately effective for emetophobia. The aim of this study is therefore to adapt and evaluate the effectiveness of the B4DT for emetophobia for a certain number of patients at the Icelandic Anxiety Clinic. Patients who seek treatment for emetophobia at KMS, fulfill inclusion criteria for the study, will be offered to participate. The study is threefold. Firstly a pilot study will be carried out where a single case experimental design is used to evaluate emetophobia symptoms across time for a group of 4-6 participants receiving the B4DT for emetophobia. Two baseline measures on SPOVI (Specific Phobia of Vomiting Inventory), EmetQ (Emetophobia Questionnaire) and overt behavior while confronted with gradually more difficult emetophobic stimuli on a video will be compared to measures at treatment phase, maintenance phase and 3- month follow-up, for each participant. The video assessment provides information on how long the patients can watch the video before and after treatment and how much distress and nausea the video provokes (the participants asked to rate their anxiety and nausea from 0-10 every five minutes). This video-assessment gives valuable information on whether patients actually react differently to emetophobic stimuli as the result of treatment. Secondly the efficacy of B4DT will be evaluated on the same measures for a larger number of participants (n = 20-25), in four to five groups. Emetophobia is a rare disorder and difficult to enroll a larger number of participant in a nation as scaresly populated as Iceland. Changes in group means and clinically significant changes on symptoms of emetophobia will be computed pre- and posttreatment.Thirdly the 12-month outcome of these patients on the same measures will be computed. If B4DT turnes out to be effective for the participants in the study, there may be reason in the coming years to do a randomized controlled study abroad on a larger number of participants. There is definitely a need to develop more robust treatment formats for this disabling condition and B4DT might meet this need.

Metode

Kvantitative analysemetoder

prosjektdeltakere

prosjektleder

Gerd Kvale

  • Tilknyttet:
    Prosjektleder
    ved Helse Bergen HF - Haukeland universitetssykehus

Kristen Hagen

  • Tilknyttet:
    Prosjektdeltaker
    ved Helse Bergen HF - Haukeland universitetssykehus

Bjarne Kristian Aaslie Hansen

  • Tilknyttet:
    Prosjektdeltaker
    ved Helse Bergen HF - Haukeland universitetssykehus

Gerd Kvale

  • Tilknyttet:
    Prosjektdeltaker
    ved Helse Bergen HF - Haukeland universitetssykehus

Lars Gøran Öst

  • Tilknyttet:
    Prosjektdeltaker
    ved Helse Bergen HF - Haukeland universitetssykehus
1 - 5 av 5